GW Pharma (GWPH) Posts Q4 EPS of 7.4c; Announces Additional Positive Epidiolex Phase 3 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
GW Pharma (GWPH) PT Raised to $208 at Cantor Fitzgerald; In Good Shape for 1st-Half 2017 NDA Submission
December 5, 2016 11:27 AM ESTCantor Fitzgerald analyst Elemer Piros reiterated a Buy rating and raised his price target on GW Pharma (NASDAQ: GWPH) to $208.00 (from $182.00), saying the company is in good sharp for NDA submission in the 1st-half of 2017.
Piros said the data the company presented at AES... More
Trading Radar for 12/5: GW Pharma (GWPH), KongZhong (KZ) Report
December 2, 2016 1:48 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Earnings:
GW Pharma (Nasdaq: GWPH) - consensus loss $1.58
Intraday or Not Specified:
Economics:
10:00am... More
